Search by Medical Condition
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for Gaucher Disease
- A Study to Evaluate Pharmacokinetic Parameters and Safety of Eliglustat Absorption Through the Mouth
- A Study to Evaluate Pharmacokinetic Parameters of Eliglustat in Healthy Volunteers Who Are CYP2D6 Extensive or Poor Metabolizers
- A Study to Evaluate Absolute Bioavailability, Absorption, Metabolism, and Excretion of Genz-112638 in Healthy Male Participants
- An Efficacy and Safety Study of AVR-RD-02 Compared to Enzyme Replacement Therapy for Treatment of Gaucher Disease Type 3
- A Study of Velaglucerase Alfa (VPRIV) in Chinese Children, Teenagers, and Adults With Type 1 Gaucher Disease
- A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED)
- Phase 1/2 Study of CAN103 in Newly Treated Subjects With Gaucher Disease
- Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3
- A Phase I Study to Compare Abcertin and EU-sourced Cerezyme® in Healthy Volunteers
- A Study of Enzyme Replacement Therapy (VPRIV) in People With Type 1 Gaucher Disease Who Were Previously Treated With Substrate Reduction Therapy
- Study to Evaluate Efficacy and Safety of Imiglucerase Treatment in Chinese Patients With Gaucher Disease Type Ⅲ
- In Utero Enzyme Replacement Therapy for Lysosomal Storage Diseases
- Phase 1/2 Clinical Trial of PR001 in Infants With Type 2 Gaucher Disease (PROVIDE)
- Assessing the Impact of Elelyso on Bone Involvement Currently Treated With Other ERTs
- Lentiviral Vector Gene Therapy - The GuardOne Trial of AVR-RD-02 for Subjects With Type 1 Gaucher Disease
- Long Term Impact of Rapid Intravenous Infusion of Velaglucerase Alfa (VPRIV)
- A Multicenter, Safety and Efficacy Study of Taliglucerase Alfa in Subjects With Type 3 Gaucher Disease
- Ambroxol Therapy for Patients With Type 1 Gaucher Disease and Suboptimal Response to Enzyme Replacement Therapy
- Study of Arimoclomol in Patients Diagnosed With Gaucher Disease Type 1 or 3
- Chronic Hepatitis C Treatment in Egyptian Children With Gaucher Disease.
- Rapid Intravenous Infusion of Velaglucerase Alfa (VPRIV) in Treatment-naive Patients With Type 1 Gaucher Disease
- Eliglustat on Gaucher Disease Type IIIB
- Safety and Efficacy of Eliglustat With or Without Imiglucerase in Pediatric Patients With Gaucher Disease (GD) Type 1 and Type 3
- Pharmacokinetics, Pharmacodynamics And Safety Study Of Elelyso(tm) In Pediatric Subjects With Type 1 Gaucher Disease
- Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3
- Phase III Study of ISU302 in Patients With Type 1 Gaucher Disease
- Role of Oxidative Stress and Inflammation in Type 1 Gaucher Disease (GD1)
- Study of the Effect of Velaglucerase Alfa (VPRIV®) on Bone-related Pathology in Treatment-naïve Participants With Type 1 Gaucher Disease
- A Study of the Effects of Renal Impairment on the Pharmacokinetics and Tolerability of Eliglustat Tartrate
- A Study of the Effects of Hepatic Impairment on the Pharmacokinetics and Tolerability of Eliglustat Tartrate
- Study of Skeletal Response to Eliglustat in Patients With Gaucher Disease
- The Effect of Velaglucerase Alfa (Vpriv) on Skeletal Development in Pediatric Gaucher Disease
- Miglustat on Gaucher Disease Type IIIB
- Taste Evaluation of Different Liquid Formulations With Eliglustat
- An Open-Label, Dose Escalation Study to Evaluate the Safety and the Pharmacokinetics of Oral PRX-112
- Intra-monocyte Imiglucerase Kinetics in Gaucher Disease
- A Study of the Tolerability, Safety, and Pharmacokinetics of ISU302 in Healthy Volunteers
- Multicenter Extension Study of Velaglucerase Alfa in Japanese Patients With Gaucher Disease
- Safety and Pharmacokinetics of Oral PRX-112 in Gaucher Disease Patients
- Human Placental-Derived Stem Cell Transplantation
- Clinical Trial of Ambroxol in Patients With Type I Gaucher Disease
- Intravenous N-acetylcysteine for the Treatment of Gaucher's Disease and Parkinson's Disease
- A Multicenter Extension Study of Taliglucerase Alfa in Adult Subjects With Gaucher Disease
- A Multicenter Extension Study of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease
- The Safety and Efficacy Study of ISU302 in Patient With Type I Gaucher Disease
- Validating a New Severity Score System for Adults With Type 1 Gaucher Disease (GD1)
- A Safety and Efficacy Study of Two Dose Levels of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease
- A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease to Evaluate Once Daily Versus Twice Daily Dosing (EDGE)
- Expanded Access Trial of Plant Expressed Recombinant Glucocerebrosidase (prGCD) in Patients With Gaucher Disease
- Treatment Protocol of Velaglucerase Alfa for Patients With Type 1 Gaucher Disease
- A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy (ENCORE)
- A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease (ENGAGE)
- A Study in Type 1 Gaucher Patients to Evaluate the Pharmacokinetics, Safety and Pharmacodynamics of AT2101
- A Long-Term Extension Study of AT2101 (Afegostat Tartrate) in Type 1 Gaucher Patients
- Switchover Trial From Imiglucerase to Plant Cell Expressed Recombinant Human Glucocerebrosidase
- Plant Cell Expressed Recombinant Human Glucocerebrosidase Extension Trial
- A Study of Oral AT2101 (Afegostat Tartrate) in Treatment-naive Patients With Gaucher Disease
- A Study of AT2101 (Afegostat Tartrate) in Adult Patients With Type 1 Gaucher Disease Currently Receiving Enzyme Replacement Therapy
- Open-Label Extension Study Evaluating Long Term Safety in Patients With Type 1 Gaucher Disease Receiving DRX008A (ERT)
- A Phase III Trial to Assess the Safety and Efficacy of Plant Cell Expressed GCD in Patients With Gaucher Disease
- A Multicenter Study of the Efficacy of Cerezyme in Testing Skeletal Disease in Patients With Type I Gaucher Disease.
- Safety and Efficacy of Cerezyme® Infusions Every 4 Weeks Versus Every 2 Weeks in Type 1 Gaucher Disease
- A Study of the Efficacy and Safety of Eliglustat Tartrate (Genz-112638) in Type 1 Gaucher Patients
- Clinical Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Miglustat in Patients With Stable Type 1 Gaucher Disease
- Phase I Single Dose-Escalation Safety Study of Human Glucocerebrosidase (prGCD)
- Stem Cell Transplant for Inborn Errors of Metabolism
- OGT 918-006: A Phase I/II Randomized, Controlled Study of OGT 918 in Patients With Neuronopathic Gaucher Disease
- Phase II Randomized Study of Alendronate Sodium for Osteopenia in Patients With Gaucher's Disease
- Phase II Study of Glucocerebrosidase in Patients With Gaucher Disease
- Bone Response to Enzyme Replacement in Gaucher's Disease
- PEG-Glucocerebrosidase for the Treatment of Gaucher Disease